Cancers 2021, 13(16), 4023; https://doi.org/10.3390/cancers13164023, August 10, 2021, by Hanbo Zhang, Stella Koumna, Frédéric Pouliot, Jean-Mathieu Beauregard and Michael Kolinsky.
Contemporary and future landscape of theranostic applications in prostate cancer with a focus on PSMA ligands. As PSMA theranostics will soon become the standard of care for the management of prostate cancer, the review underscores the importance of integrating nuclear medicine physicians into the multidisciplinary team. Read the article >>Other news & events
- News04.12.2025

#BlueNovemberWithRadiotheranostics for Urologists, Oncologists and Nuclear Medicine physicians
Read more - News10.11.2025

#BlueNovemberWithRadiotheranostics - The VISION trial: Meet Dr Alison Armour
Read more - News06.11.2025

Oncidium Foundation USA Achieves 501(c)(3) Status to Expand Patient Access to Nuclear Medicine and Theranostics
Read more




